ArticleOncotarget2016
Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 89 citations in OpenAlex.
- Intraoperative Molecular Imaging Combined With Positron Emission Tomography Improves Surgical Management of Peripheral Malignant Pulmonary Nodules.Annals of surgery · 2017Trial
- Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Integrating Tumor Budding and the Invasive-Front Microenvironment in Colorectal Carcinoma: An Exploratory Histopathological Score-Based Association Study.International journal of molecular sciences · 2026Article
- Advances in methotrexate nano-formulations to enhance therapeutic efficacy against drug-resistant breast cancer.Discover nano · 2026Review
- Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.EJNMMI research · 2025Article
- Review
- Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins.Nature chemical biology · 2025Article
- The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death.Molecular cancer therapeutics · 2025Article
- The develop of persistent luminescence nanoparticles with excellent performances in cancer targeted bioimaging and killing: a review.Journal of nanobiotechnology · 2025Review
- Cisplatin-loaded UiO-66-NHHeliyon · 2025Article
- Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Oncogene · 2025Review
- Systematic review of fluorescence-guided surgery in pituitary neuroendocrine tumours.Endocrine oncology (Bristol, England) · 2025Review
- Engineered RBC-derived nanovesicles functionalized with tumor-targeting ligands: A comparative study on breast cancer targeting efficiency and biocompatibility.Open medicine (Warsaw, Poland) · 2025Article
- Immunohistochemical Evaluation of Cathepsin B, L, and S Expression in Breast Cancer Patients.Molecular imaging and biology · 2024Article
- Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?International journal of molecular sciences · 2024Review
- Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles' Biodistribution in Cancer.Molecular pharmaceutics · 2024Article
- Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.Journal of ovarian research · 2024Review
- Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.International journal of molecular sciences · 2024Review
- Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis.Chemical science · 2024Review
- Advances in Lung Cancer Treatment Using Nanomedicines.ACS omega · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer. To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important. Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients. False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%. In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC). Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs. Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor. In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases. In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.